Medical diagnostics provider Biodesix Inc. and spectrometry developer Bioyong Technology Co. Ltd. have entered into an international collaboration agreement where Bioyong will develop and commercialize a version of Biodesix’s VeriStrat proteomic blood test, a precision medicine diagnostic for patients with non-small cell lung cancer (NSCLC). Bioyong will pay Biodesix approximately $38 million over the course of the collaboration. The system will be designed for clinical use in China, with potential expansion into other Asia-Pacific countries. With nearly 850,000 new lung cancer diagnoses predicted in 2020, China represents approximately 37 percent of new cases worldwide. “We believe that cancer is a global problem,” said David Brunel, CEO of Biodesix. “Patients and their physicians everywhere want cancer treatment that is grounded in precision medicine including therapy selection that reflects the full spectrum of biological information provided by our multivariate, molecular and proteomic assays. By collaborating with Bioyong, we are taking a major step toward making our technology available to a large portion of the world’s lung cancer patients.” Biodesix is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Bioyong Technology is a developer of mass spectrometry technologies.